Effect of mutant p53 stability on tumorigenesis and drug design

May 15, 2008

In the May 15th issue of G&D, Dr. Guillermina Lozano (MD Anderson Cancer Center) and colleagues reveal how the stabilization of a mutated form of p53 affects oncogenesis, and lends startling new insight into the potential pitfalls of using Mdm2 inhibitors for cancer therapy.

"Our data are both exciting and sobering: we must classify tumors with respect to p53 mutation status prior to treatment,” emphasizes Dr. Lozano.

One function of the p53 tumor suppressor is to arrest the cell cycle in response to DNA damage. For years it has been the focus of intense cancer research, as mutations in p53 prevent cell cycle arrest and lead to unregulated cell growth. p53 is one of the most commonly mutated genes in human cancers.

Dr. Lozano’s research team now demonstrates how a particular mutated form of p53 – which is prevalent in human cancers – can become stable in some cells, where it facilitates cancer formation and metastasis. The scientists found that mutant p53 is inherently unstable in normal tissues, but can become stable in some cells.

The researchers discovered that the acquisition of additional mutations the p53-antaogonist, Mdm2, could effectively stabilize mutant p53. Transgenic mice engineered to harbor such mutations displayed enhanced tumor formation and metastasis, compared with littermates lacking only p53.

Targeted drug therapies aimed at activating p53 tumor suppressor activity via the disruption of the normal Mdm2/wild-type-p53 interaction will also disrupt the Mdm2/mutant-p53 interaction. Thus, these Mdm2 inhibitors will succeed in stabilizing mutant p53, and fail in preventing tumor metastasis.

Source: Cold Spring Harbor Laboratory

Explore further: Researchers find nine diabetes variants that can greatly increase risk from disease

add to favorites email to friend print save as pdf

Related Stories

A chaperone for the 'guardian of the genome'

Sep 07, 2011

The protein p53 plays an essential role in the prevention of cancer by initiating the controlled death of a cell with damaged genes which is in danger to transform into a cancerous cell. The heat shock protein Hsp90, in turn, ...

Novel compound selectively kills cancer cells

Jul 13, 2011

A cancer cell may seem out of control, growing wildly and breaking all the rules of orderly cell life and death. But amid the seeming chaos there is a balance between a cancer cell's revved-up metabolism and skyrocketing ...

New therapeutic target for lung cancer

Mar 31, 2011

A new therapeutic target for lung cancer has been discovered by researchers at Seoul National University. It was found that a variant of the protein AIMP2 is highly expressed in lung cancer cells and also that patients demonstrating ...

Cancer is a p53 protein aggregation disease

Mar 29, 2011

Protein aggregation, generally associated with Alzheimer's and mad cow disease, turns out to play a significant role in cancer. In a paper published in Nature Chemical Biology, Frederic Rousseau and Joost Schymkowitz of VIB ...

Recommended for you

Gene variant that dramatically reduces 'bad' lipids

2 hours ago

In the first study to emerge from the UK10K Project's cohort of samples from the general public, scientists have identified a rare genetic variant that dramatically reduces levels of certain types of lipids in the blood. ...

New diagnostic method identifies genetic diseases

4 hours ago

People with genetic diseases often have to embark on an odyssey from one doctor to the next. Fewer than half of all patients who are suspected of having a genetic disease actually receive a satisfactory diagnosis. Scientists ...

User comments : 0